- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- Senate passes Drug Quality and Security Act
- FDA advisory panel to consider OTC status of NSAIDs
- Diplomat becomes distributor of recently approved cancer drug
- FDA advisory committees turn down Primatene HFA application for OTC status
FLORHAM PARK, N.J. The Food and Drug Administration has approved a nonstimulant drug for treating attention deficit hyperactivity disorder.
Shionogi announced Monday the approval of Kapvay (clonidine hydrochloride), an extended-release drug for treating ADHD in children and adolescents ages 6 to 17 years. The company said Kapvay was the only formulation of clonidine hydrochloride approved for treating ADHD and the first ADHD treatment approved for use as an add-on therapy to stimulant drugs.
“The FDA approval of Kapvay represents an exciting milestone in the field of ADHD,” Shionogi chief medical officer Donald Manning said. “We look forward to providing this important, beneficial treatment for ADHD to patients, both as monotherapy and add-on therapy to stimulants.”